Eli Lilly and Company (LLY)vsWarby Parker Inc (WRBY)
LLY
Eli Lilly and Company
$934.60
+9.80%
HEALTHCARE · Cap: $760.43B
WRBY
Warby Parker Inc
$22.53
-3.10%
HEALTHCARE · Cap: $2.63B
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 7375% more annual revenue ($65.18B vs $871.90M). LLY leads profitability with a 31.7% profit margin vs 0.2%. LLY trades at a lower P/E of 37.0x. LLY earns a higher WallStSmart Score of 78/100 (B+).
LLY
Strong Buy78
out of 100
Grade: B+
WRBY
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+30.9%
Fair Value
$31.81
Current Price
$22.53
$9.28 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 101 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 44.9%
Revenue surging 42.6% year-over-year
Earnings expanding 51.4% YoY
No standout strengths identified
Areas to Watch
Premium valuation, high expectations priced in
Elevated debt levels
Trading at 31.5x book value
0.0% earnings growth
ROE of 0.5% — below average capital efficiency
0.2% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 31.7% and operating margin at 44.9%. Revenue growth of 42.6% demonstrates continued momentum.
Bull Case : WRBY
Revenue growth of 11.2% demonstrates continued momentum.
Bear Case : LLY
The primary concerns for LLY are P/E Ratio, Debt/Equity, Price/Book. Debt-to-equity of 1.60 is elevated, increasing financial risk.
Bear Case : WRBY
The primary concerns for WRBY are EPS Growth, Return on Equity, Profit Margin. A P/E of 2147.0x leaves little room for execution misses. Thin 0.2% margins leave little buffer for downturns.
Key Dynamics to Monitor
LLY profiles as a growth stock while WRBY is a value play — different risk/reward profiles.
WRBY carries more volatility with a beta of 2.08 — expect wider price swings.
LLY is growing revenue faster at 42.6% — sustainability is the question.
LLY generates stronger free cash flow (678M), providing more financial flexibility.
Bottom Line
LLY scores higher overall (78/100 vs 34/100), backed by strong 31.7% margins and 42.6% revenue growth. WRBY offers better value entry with a 30.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Warby Parker Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Warby Parker Inc. is a pioneering force in the direct-to-consumer eyewear sector, established in 2010 to transform the optical experience through a combination of online convenience and an expanding network of retail locations. The company emphasizes stylish, affordable prescription eyewear and sunglasses, uniquely positioning itself to attract a diverse customer base. Its socially responsible business model, highlighted by the "Buy a Pair, Give a Pair" initiative, underscores a commitment to community welfare, providing eyewear to those in need. With a strong brand identity and innovative marketing approaches, Warby Parker is poised for sustained growth and resilience in an increasingly competitive industry.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?